The p53 tumor suppressor protein inhibits tumor formation, in part by inducing apoptosis, which is inhibited by anti-apoptotic Bcl-2 family members Bcl-2 and adenovirus E1B 19K. We have identi®ed p53-apoptotic signaling events which are targeted for inhibition by E1B 19K. Apoptotic signaling by p53 induced a Bid-independent conformational change in Bax, a Bax-Bak interaction, release of cytochrome c and Smac/DIABLO from mitochondria, caspase-9 and -3 activation, cleavage of known caspase substrates, and apoptosis. When p53-dependent apoptosis was blocked by E1B 19K expression, E1B 19K bound Bak, and the Bax-Bak interaction was inhibited. Cytochrome c and Smac/DIABLO release from mitochondria was also inhibited in E1B 19K expressing cells and cells remained viable. After a prolonged p53 death stimulus, the inhibition of the mitochondrial death checkpoint by E1B 19K failed, and cytochrome c and Smac/DIABLO were released from mitochondria, and became degraded. Despite this eventual failure to inhibit the mitochondrial checkpoint, caspase-9 and -3 were not activated, and cells remained viable even upon treatment with an exogenous death stimulus. Thus, p53 induces apoptosis in part through Bax and Bak, and even an incomplete inhibition of this mitochondrial checkpoint may be sucient to confer resistance to cell death.
Introduction p53 protects cells against DNA damage-induced stresses, which could lead to transformation and tumorigenesis. Mutations in p53 have been found in over 50% of all human tumors with loss of the gene seen in the majority of tumor types (Hollstein et al., 1991) . In addition to direct loss of the p53 gene, disruption of key components in the p53 pathway have been implicated in a vast number of human tumors (Levine et al., 1991; Ryan et al., 2001; Vogelstein and Kinzler, 1992) . Therefore, it is clear that understanding the pathway through which p53 protects the cell against oncogenic transformation, and how this pathway can be inhibited, is essential in elucidating targets for future cancer therapy.
Protection against oncogenic transformation occurs, at least in part by stabilization of the p53 protein and transcriptional activation or repression of a variety of p53 target genes, which implement cell cycle arrest and apoptosis, depending on physiological conditions (Ryan et al., 2001) . p53 target genes most often implicated in the apoptotic pathway include the death receptor Fas/ApoI gene, as well as genes required for propagation of the signal through mitochondria, such as bax, bak, puma and noxa, (Kannan et al., 2001; Miyashita and Reed, 1995; Nakano and Vousden, 2001; Oda et al., 2000) . In addition to stimulating the expression of pro-apoptotic genes, p53 represses transcription of anti-apoptotic bcl-2 (Miyashita et al., 1994) , whose gene product is an antagonist of proapoptotic Bax and Bak . Furthermore, activation of Cdc42 by p53 causes the phosphorylation and subsequent inactivation of Bcl-2 . Thus, p53 may function both by stimulating the function of pro-apoptotic proteins and by inactivating the function of anti-apoptotic proteins. However, the individual and collective roles of these and other p53-regulated gene products in p53-dependent apoptosis, remains to be determined.
In order to study the p53-mediated apoptotic pathway, we previously derived baby rat kidney (BRK) epithelial cells that are transformed by the adenovirus E1A oncogene and a temperature-sensitive p53 mutant, p53
val135 (Debbas and White, 1993) . At the restrictive temperature of 38.58C, p53 is in a mutant conformation, which inhibits p53 function and allows transformation of the primary BRK cells by E1A. At the permissive temperature of 328C, however, p53 is returned to its wild-type, active conformation and mediates E1A-induced, p53-dependent apoptosis, as a direct result of p53 function (Chiou et al., 1994b; Debbas and White, 1993; Sabbatini et al., 1995a; Thomas and White, 1998) . In this setting p53-mediated apoptosis is dependent on the transcriptional activity of p53, in that BRK cells transformed with E1A and a transcriptionally defective temperature-sensitive p53 mutant, p53 (22) (23) val135 ), do not undergo apoptosis at the permissive temperature (Sabbatini et al., 1995b) . Although induction of wild-type p53 results in the transcriptional activation of bax (Han et al., 1996a) , this is not sucient for cell death, in that the p53 mutant, p53tsDPP, retains the ability to activate bax expression but fails to induce apoptosis (Sakamuro et al., 1997) . bax de®cient cells, however, display a decreased ability to undergo p53-mediated apoptosis induced by E1A and cytotoxic agents, which suggests the possible contribution of Bax to p53-induced apoptosis (McCurrach et al., 1997) .
Inhibition of the p53-mediated apoptotic pathway can lead to oncogenic transformation. Propagation of the wild-type p53 apoptotic signal can be inhibited in the transformed BRK cells by expression of either Bcl-2 or the adenovirus Bcl-2 homologue, the E1B 19K protein (Chiou et al., 1994a; Debbas and White, 1993; Sabbatini et al., 1995a) . E1B 19K has been shown to bind and to inhibit pro-apoptotic Bcl-2 family members Bax, Bak, and NBK/Bik (Boyd et al., 1995; Farrow et al., 1995; Han et al., 1996a,b) . There is evidence that E1B 19K interactions with Bax and/or Bak may be required for inhibition of apoptosis by TNF-a and during virus infection (A Cuconati, manuscript in preparation; Farrow et al., 1995; Perez and White, 2000; . However, it is not known if Bax and/or Bak interact with E1B 19K in the p53-mediated apoptosis pathway or whether these interactions are involved in E1B 19K inhibiting p53-dependent cell death.
Functional analysis of Bax and Bak suggest that their pro-apoptotic activity may be stimulated by protein ± protein interactions, which induce changes in their conformation. Changes in Bax and Bak protein conformation are associated with oligomerization, membrane insertion, and possibly formation of mitochondrial membrane pores, similar to that of the bacterial pore forming toxins (Gazit et al., 1998; Gerber and Shai 2000; Gilbert et al., 1999; Suzuki et al., 2000; Tan et al., 1999; Wei et al., 2001) . In death receptor-mediated signaling Bid is cleaved to tBid by caspase-8 which promotes binding of tBid to Bax and Bak (Desagher et al., 1999; Eskes et al., 2000; Li et al., 1998; Luo et al., 1998; Perez and White, 2000) . This binding causes the conformational changes in Bax and Bak, which are associated with their oligomerization in the mitochondrial membrane and propagation of the death signal by promoting the release of mitochondrial proteins.
Cells de®cient for both Bax and Bak do not release cytochrome c from mitochondria upon various death stimuli and do not undergo apoptosis (K Degenhardt, manuscript in preparation; Wei et al., 2001) . Once released from mitochondria, cytochrome c and Smac/ DIABLO can serve as cofactors for the activation of caspases, which are involved in the eventual destruction of the cell (Wolf and Green, 1999) . Cytochrome c, along with Apaf-1 and caspase-9, form the apoptosome, a multi-protein apoptosis-inducing complex, which allows the autocatalytic cleavage and activation of caspase-9 (Li et al., 1997) . Smac/DIABLO acts by antagonizing the inhibitors of apoptosis, such as XIAP and cIAP-1, which are bound to and prevent activation of caspase-9 (Du et al., 2000; Verhagen et al., 2000) . Active caspase-9, in turn activates other caspases including caspase-3, which cleave cellular substrates such as PARP and lamins, which collectively lead to destruction of the cell. Activation of caspases is required to carry out p53-mediated apoptosis, in that pharmacological inhibition of the caspases blocks p53-dependent apoptosis . Taken together, this implicates a role for Bax and Bak and the release of proteins such as cytochrome c and Smac/ DIABLO from mitochondria to facilitate caspase activation in p53-dependent apoptosis.
How anti-apoptotic Bcl-2 family members inhibit p53-dependent apoptosis is not known, but may be related to inhibition of Bax and Bak function at mitochondria. In the TNF-a-mediated apoptosis pathway, E1B 19K expression blocks cell death at the mitochondria by binding to Bax and Bak to inhibit their oligomerization, the release of cytochrome c and Smac/DIABLO, caspase-9 and -3 activation, and cell death (Perez and White, 2000; ). These ®ndings prompted us to examine Bax and Bak regulation in mitochondria during p53-dependent death signaling. Here we show wild-type p53-directed apoptosis was signaled through Bax and Bak in mitochondrial to promote caspase-9 and -3 activation, and apoptosis. The E1B 19K protein bound to Bak, and interfered with both the Bax-Bak interaction, the normal release of cytochrome c and Smac/DIABLO from mitochondria, caspase-9 and -3 activation, and apoptosis. Eventually cytochrome c and Smac/DIABLO were released from mitochondria in E1B 19K expressing cells, but their release was unproductive and led to their degradation rather than to caspase activation. Thus even an incomplete inhibition of the mitochondrial apoptotic checkpoint by E1B 19K can confer resistance to apoptosis.
Results

Prolonged inhibition of p53-dependent apoptosis by E1B 19K
In An1 cells, E1A-induced, p53-mediated apoptosis occurs when the cells are grown at the permissive temperature (328C) for p53, which is inhibited by E1B 19K expression in 19K1 cells (Debbas and White, 1993 (Figure 1a) . Few, if any, cells contained less than 2N DNA which would correspond to the sub-G1 peak of apoptotic cells, or more than 4N DNA content which would correspond to polyploid cells ( Figure 1a) . Once incubated at the permissive temperature, apoptosis was observed at day 1 and was nearly complete by day 3 in the EV V5 cells, as indicated by the substantial increase in cells with less than 2N DNA content in the sub-G1 peak ( Figure 1a ). Because cell death was virtually complete in EV V5 cells by day 4 at the permissive temperature, further time-points were not examined. These results were essentially the same as those reported from the similarly derived An1 cells (Debbas and White, 1993) .
As previously observed in the 19K1 cells, the presence of the E1B 19K protein in the 19K V5 cells blocked p53-mediated cell death, even after a prolonged 10-day wild-type p53 death signal (Sabbatini et al., 1995a, and Figure 1b) . In fact, cells remained viable even beyond 15 days at the permissive temperature (see below). No sub-G1 population was produced during 10 days at the permissive temperature for wild-type p53 (Figure 1b) . However, an overall decrease in the population of cells with 2N DNA content and an increase in the 44N DNA content population was observed in the 19K V5 cells (Figure 1b ). Although p53-dependent growth arrest occurred after 1 day at the permissive temperature, the number of viable cells remained constant (Sabbatini et al., 1995a Bax has been shown to undergo conformational changes in response to apoptotic stimuli, which lead to the exposure of epitopes on the amino and carboxy termini (Desagher et al., 1999; Hsu and Youle, 1998; Nechushtan et al., 1999; Perez and White, 2000; Wei et al., 2001) . In order to determine if wildtype p53 propagates its apoptotic signal through Bax, we monitored Bax conformation at the permissive and restrictive temperatures for p53. Whole cell extracts of the wild-type p53-induced An1 and 19K1 cells were examined over a 10-day period. Bax protein levels increased in the An1 and 19K1 whole cell extracts upon wild-type p53 induction, independent of the presence of E1B 19K and consistent with transcrip- A conformational change in Bax was examined by indirect immuno¯uorescence with an antibody that recognizes the Bax amino terminus (Bax NT). When both the EV V5 and 19K V5 cells were grown at the nonpermissive temperature (38.58C), only background staining was observed with the Bax NT antibody (Figure 2b ). In contrast, in both the EV V5 and 19K V5 cells incubated at the permissive temperature for wildtype p53, the amino terminal conformational change in Bax occurred, as indicated by a bright punctate staining pattern corresponding to mitochondria ( Figure  2b ). Approximately 40% of both the EV V5 and 19K V5 cells visualized by immuno¯uorescence became positive for Bax mitochondrial staining upon induction of the wild-type p53 signal. Thus p53 signals a conformational change in the Bax amino terminus, which is not prevented by E1B 19K expression. In addition to indirect immuno¯uorescence, immunoprecipitations were performed using the Bax NT antibody to examine the amino terminal conformational change in Bax and the potential co-precipitation of Bax with cellular proteins. In vitro, non-ionic detergents, such as Triton X-100 have been shown to duplicate the amino terminal conformational change in Bax induced in vivo by death signaling, whereas the use of the zwitter-ionic CHAPS detergent has been used to maintain Bax and Bak in their native cellular conformation (Antonsson et al., 2000; Hsu and Youle, 1997; . Extracts from EV V5 and 19K V5 cells in Triton X-100 buer had nearly equal amounts of Bax immunoprecipitated with the Bax NT antibody independent of p53 induction ( Figure  2c ). However, in the presence of the CHAPS buer alone, we observed an increase in the amount of Bax immunoprecipitated by the Bax NT antibody by day 1 at the permissive temperature as compared to that immunoprecipitated at the restrictive temperature (Figure 2c ). This suggested that an amino terminal conformational change occurred in Bax in response to wild-type p53 signaling. In agreement with the indirect immuno¯uorescence, the amino terminal conformational change in Bax was not inhibited by the presence of the E1B 19K protein (Figure 2c ). Therefore E1B 19K functions downstream of the conformational change in Bax induced by the wild-type p53 death signal.
p53 signaling induces a Bax-Bak interaction, which was inhibited by E1B 19K
Given that Bax and Bak heterodimerize (Figure 2c) . Expression of E1B 19K delayed the BaxBak co-immunoprecipitation until day 3, and the interaction was observed through day 6 at the permissive temperature in the 19K V5 cells (Figure 2c ). E1B 19K also interacted with Bax by day 3 through day 6 at the permissive temperature in the 19K V5 cells, with no Bax-E1B 19K interaction observed at the restrictive temperature (Figure 2c ). Thus E1B 19K expression delayed the wild-type p53-induced Bax-Bak interaction and interacted with Bax upon wild-type p53 induction.
Immunoprecipitations with the V5 epitope antibody were also used to examine the interactions of E1B 19K with Bax and Bak. Immunoprecipitation of E1B 19K with the V5 antibody resulted in equal amounts of E1B 19K immunoprecipitated from the 19K V5 cells at the permissive and restrictive temperatures ( Figure  2c ). Co-immunoprecipitation of Bax with E1B 19K was observed at days 3 and 6 at the permissive temperature, whereas no E1B 19K-Bax interaction was observed at the restrictive temperature (Figure 2c ). Bak also co-immunoprecipitated with E1B 19K, but this interaction was independent of p53 functional status as it occurred at both the permissive and restrictive temperatures (Figure 2c) . Thus, the interaction between Bak and 19K is constitutive and the interactions between Bax and Bak and Bax and E1B 19K were p53 inducible. These data suggest that the block to apoptosis by E1B 19K may be by delaying the interaction between Bax and Bak through interaction of E1B 19K with Bak. Alternatively, the E1B 19K-Bax and E1B 19K-Bak interactions may inhibit the formation of a functionally active Bax-Bak complex.
p53-induced release of mitochondrial proteins is inhibited by E1B 19K
In order to determine if the wild-type p53-mediated apoptosis signal induces the release of mitochondrial proteins, and if E1B 19K has an aect on this signal, we monitored the release of cytochrome c and Smac/ DIABLO from mitochondria, in the presence and absence of E1B 19K. Indirect immuno¯uorescence was performed on An1 and 19K1 cells (and the 19K V5 and EV V5 cells, data not shown), at the restrictive and permissive temperatures. In both the An1 and 19K1 cell lines, cytochrome c and Smac/DIABLO were exclusively mitochondrial in cells expressing mutant p53 at 38.58C as seen by the punctate staining ( Figure  3) . The An1 and 19K1 cells were also stained using Mitotracker, a known mitochondrial marker, as a control for mitochondria staining, which was consistent with cytochrome c and Smac/DIABLO at the non-permissive temperature (data not shown). In the 
An1 cells, the induction of wild-type p53 resulted in the release of cytochrome c and Smac/DIABLO from mitochondria by day 2 at the permissive temperature, as indicated by the decrease in the number of cells displaying punctate mitochondrial staining for cytochrome c and Smac/DIABLO. By day 2 at the permissive temperature for p53, less than 50% of the An1 cells displayed punctate staining for cytochrome c and less than 20% of the An1 cells displayed punctate staining for Smac/DIABLO (Figure 3) . Although we did detect diuse cytosolic staining of both cytochrome c and Smac/DIABLO in some cells, a complete loss of staining was observed in most cases. This suggested that degradation of cytochrome c and Smac/DIABLO may accompany their release from mitochondria.
Expression of the E1B 19K protein in the 19K1 cells dramatically disrupted the release of mitochondrial proteins cytochrome c and Smac/DIABLO, upon induction of the wild-type p53 signal (Figure 3) . Eventually, the block to the mitochondrial checkpoint by E1B 19K failed after prolonged exposure to wildtype p53 and resulted in the release from mitochondria of both cytochrome c and Smac/DIABLO beginning at day 3 and continuing through day 10 at the permissive temperature (Figure 3) . Nonetheless, the cells still remained viable (Figure 1) . As in the An1 cells, we observed some cells displaying no cytosolic staining for cytochrome c and Smac/DIABLO. These data suggested that disruption of the wild-type p53 mitochondrial checkpoint by E1B 19K inhibits the normal release of cytochrome c and Smac/DIABLO from mitochondria.
p53 stimulates the degradation of cytochrome c and Smac/DIABLO Previously we have observed accumulation of cytochrome c and Smac/DIABLO in the cytosol of cells which had released these proteins from mitochondria upon induction of other death signals (Perez and White, 2000; ). Because we did not always observe diuse cytosolic staining of released cytochrome c and Smac/ DIABLO by indirect immuno¯uorescence, we suspected that these proteins might be degraded upon release from mitochondria. Whole cell lysates from An1 and 19K1 cells grown at the permissive and restrictive temperatures for p53 were analysed for cytochrome c and Smac/DIABLO levels. In An1 cells, both cytochrome c and Smac/DIABLO levels decreased upon induction of wild-type p53 by day 3 at the permissive temperature, as compared to the levels of these proteins at the restrictive temperature (Figure 4a) . Similarly, cytochrome c and Smac/ DIABLO levels decreased upon induction of wildtype p53 in the 19K1 cells, as compared to the levels at the restrictive temperature, but the decrease is not observed until day 7 at the permissive temperature (Figure 4a ), although the cells still remained viable (Figure 1b) .
In order to con®rm if degradation of cytochrome c and Smac/DIABLO occurred upon release from mitochondria, cellular fractionation of the An1 and 19K1 cells was performed at the permissive and restrictive temperatures for p53. In An1 cells, mitochondrial levels of both cytochrome c and Smac/ DIABLO decreased by day 1 at the permissive temperature (Figure 4b ). Although delayed in 19K1 cells, cytochrome c and Smac/DIABLO were released from mitochondria beginning at day 6 at the permissive temperature (Figure 4b) . Release of cytochrome c and Smac/DIABLO from mitochondria in both the An1 and 19K1 cells did not result in accumulation of these proteins in the soluble cytosolic fraction, suggesting cytochrome c and Smac/DIABLO were degraded upon release (Figure 4b ). Although the detection of Smac/ DIABLO in the mitochondrial fraction was limited, the decrease in the level of Smac/DIABLO in mitochondria and the absence of accumulation of cytosolic Smac/ DIABLO suggested the protein was degraded upon release from mitochondria. A low level of cytosolic cytochrome c was observed in both the An1 and 19K1 cells, but this level did not increase upon wild-type p53 induction. The decrease in cytochrome c and Smac/ DIABLO was not due to the destruction of mitochondria, in that the levels of a known mitochondrial protein, cytochrome oxidase IV (CoxIV) were unchanged in both the An1 and 19K1 cells (Figure 4b) , and cells maintained a mitochondrial membrane potential as indicated by positive Mitotracker staining (data not shown). Thus, this suggested that both cytochrome c and Smac/DIABLO were degraded upon release from mitochondria, and expression of E1B 19K delayed the release, but did not inhibit degradation.
In various apoptotic death signaling pathways including the p53-mediated apoptosis pathway, release of cytochrome c is associated with the translocation of Bax to the mitochondria (Gao et al., 2001 ). Because our data suggested a role for Bax and Bak in wild-type p53 apoptosis, we examined Bax and/or Bak mitochondrial translocation. In An1 and 19K1 cells, Bax did not fractionate with mitochondria at the restrictive temperature for p53 (Figure 4b ). However, increasing amounts of Bax fractionated with mitochondria in An1 cells beginning at day 1 of the permissive temperature (Figure 4b ). Although delayed in the 19K1 cells, Bax did fractionate with the mitochondria beginning at day 3 at the permissive temperature (Figure 4b ). Localization of Bak and E1B 19K did not change upon induction of wild-type p53, in that Bak and 19K fractionated with the mitochondria and heavy membranes, independent of p53 activity (Figure 4b ). These data suggested that Bak and E1B 19K remained in mitochondria independent of p53 signaling, whereas Bax translocated to mitochondria upon induction of wild-type p53. Finally, E1B 19K expression may delay the fractionation of Bax with mitochondria perhaps by binding to and interfering with Bak, which may prevent the formation of Bax-Bak complexes in the mitochondria.
Stimulation of Bax function in mitochondria has been shown to require the generation of the pro-apoptotic tBid in other apoptotic signaling pathways. In order to determine if Bid was involved in wild-type p53-mediated apoptosis, we looked for the generation of tBid in the An1 and 19K1 cells upon induction of wild-type p53. Neither a decrease in Bid levels nor the generation of tBid was observed in An1 or 19K1 cells at the permissive or restrictive temperatures for p53 (Figure 4a) . Furthermore, localization of Bid was unchanged and Bid remained in the cytosol independent of induction of wild-type p53 in both the An1 and 19K1 cells (Figure 4b ). These data suggested the propagation of the wild-type p53 signal does not depend on Bid or tBid, and that Bax translocation to mitochondria occurs by a Bid-independent mechanism.
Caspase-9 and -3 are activated in p53-dependent apoptosis Cytochrome c and Smac/DIABLO function to enable caspase-9 and -3 activation, which lead to the cleavage of cellular substrates PARP and lamin to implement apoptotic cell death (Goyal, 2001; Wolf and Green, 1999) . As cytochrome c and Smac/DIABLO were eventually released from mitochondria upon induction of p53-mediated apoptosis in E1B 19K expressing cells, we wanted to determine if these levels of cytochrome c and Smac/DIABLO release were sucient to promote caspase activation. An1 and 19K1 whole cell lysates obtained at the restrictive and permissive temperatures for p53 were analysed for caspase activation by Western blotting.
Induction of the wild-type p53 death signal in An1 cells resulted in the activation of both caspases-9 and -3 by day 1 which increased through day 3 as seen by the disappearance of procaspase-9 and -3, and by the appearance of the cleaved products, p37 and p17, respectively (Figure 5a ). In contrast, no detectable processing of procaspase-8 was observed at any timepoint (Figure 5a) . Cleavage of the known caspase 58C and transferred to the permissive temperature of 328C for 0 to 10 days, as indicated. Cells were subjected to subcellular fractionation. The total, representing the whole cell lysate; (S100), representing the cytosolic fraction; and the mitochondria, representing mitochondria and heavy membrane fraction, were run on SDS ± PAGE and analysed by Western blot using antibodies to cytochrome c, Smac/DIABLO, CoxIV, Bax, Bak, Bid, and E1B 19K as indicated Oncogene Inhibition of the p53-induced Bax-Bak interaction by E1B 19K H Henry et al substrates PARP and lamin was observed with similar kinetics to that of caspase-9 and -3 activation ( Figure  5b ). Activation of both caspase-9 and -3, as well as downstream substrate cleavage, was inhibited in E1B 19K expressing cells even after a prolonged death stimulus (10 days (Figure 5a) ). We did not detect caspase-9 or -3 activation in 19K1 cells, even when grown at the permissive temperature for as long as 15 days (data not shown). IAP-1 and XIAP, which are known inhibitors of caspase-9 and -3, become either processed or degraded during p53-mediated apoptosis in An1 cells, whereas IAP-2 was not substantially aected ( Figure 5c ). Consistent with the inhibition of apoptosis signaling events downstream of the mitochondria by E1B 19K, IAP-1 and XIAP were unaected in E1B 19K expressing cells at the permissive temperature (Figure 5c ). These results suggested that the apoptotic pathway initiated by wild-type p53 involves the activation of caspase-9 and -3, and that despite the eventual failure of E1B 19K to block release of cytochrome c and Smac/DIABLO, activation of the apoptotic events downstream of mitochondria were still inhibited. Thus even a partial inhibition to the mitochondrial checkpoint by E1B 19K is sucient to inhibit caspase-9 and -3 activation and apoptosis.
Disruption of the mitochondria checkpoint confers resistance to apoptosis
Because we did not observe activation of caspases-9 and -3 in the 19K1 cells (Figure 5a ) even under conditions where cytochrome c and Smac/DIABLO had been released (Figure 4b ), we questioned whether the unproductive release and degradation of mitochondrial proteins in the presence of E1B 19K could confer resistance to apoptosis by another death stimulus. It has been shown that apoptosis induced by STS Figure 5 Caspase-9 and -3 are activated in p53-dependent apoptosis. (a) An1 cells and 19K1 cells were grown at the restrictive temperature of 38.58C and transferred to the permissive temperature of 328C for 0 to 10 days, as indicated. HeLa cells treated with TNF-a/CHX for 4 h were used as controls for the cleaved caspase products. Whole cell lysates were collected, run on SDS ± PAGE, and analysed by Western blotting using antibodies to caspases-9, -3, and -8. The pro-caspase form and cleaved products are indicated to the left. It should be noted that a low level of background caspase activation was detected in the 19K expressing cells. However this level is not induced by the wild-type p53 signal. (b) Western blot analysis was performed using antibodies to lamin A/C and PARP. The full-length and cleaved products are indicated to the left. (c) Western blot analysis was performed using antibodies to IAP-1, IAP-2, XIAP, and actin, indicated to the left requires the release of cytochrome c from mitochondria, and cytochrome c de®cient cells are resistant to STS-mediated cell death . Since E1B 19K expression caused the p53-dependent unproductive release of cytochrome c from mitochondria and its eventual degradation, we examined if those cells displayed resistance to apoptosis induced by STS. 19K1 cells were incubated at the restrictive temperature where cytochrome c and Smac/DIABLO were localized to mitochondria or incubated at the permissive temperature for an extended time (15 days) to generate a signi®cant population of viable cells that had released and degraded cytochrome c and Smac/Diablo. By day 15 at the permissive temperature, approximately 50% of the cells had released cytochrome c and 95% had released Smac/DIABLO (data not shown). The 19K1 cells growth arrested by day 2 at the permissive temperature and remained growth arrested at day 15 suggesting p53 was still functioning in these cells (data not shown). These 19K1 cells were then treated with increasing concentrations of STS for 24 h and then monitored for viability.
Under conditions where p53 was inactive (0 days at 328C) and cytochrome c and Smac/DIABLO were retained in the mitochondria, STS induced cell death of 19K1 cells in a concentration dependent manner as indicated by the increasing number of round¯oating cells observed under phase contrast microscopy ( Figure  6a ). In contrast, in 19K1 cells where a signi®cant proportion had degraded cytochrome c and Smac/ DIABLO (15 days at 328C) STS had little aect on their morphology, in that the cells looked relatively healthy and¯at as compared to the untreated cells (Figure 6a) . In order to measure the amount of cell death induced by STS in these 19K1 cells, cells were collected and viability assayed using Trypan blue exclusion. The 19K1 cells grown at the restrictive temperature (0 days at 328C) died in a concentrationdependent manner, with approximately 40% cell death with treatment of 2 mM STS (Figure 6b ). In contrast, cell death induced by STS was largely inhibited in the cells subjected to a prolonged wild-type p53-induced apoptosis signal (15 days at 328C) (Figure 6b ). These data suggested that the unproductive release and degradation of cytochrome c and Smac/DIABLO in the presence of E1B 19K can confer resistance to apoptosis induced by STS.
Discussion
Activation of p53 in response to genotoxic stresses is known to induce apoptosis and protect against cellular transformation. We have deciphered molecular events involved in the induction of wild-type p53-mediated apoptosis and found that a Bid-independent, conformational change in Bax, a Bax-Bak interaction, release of cytochrome c and Smac/DIABLO, and caspase-9 and -3 activation accompanied p53-mediated cell death. Inhibition of this p53-mediated death signaling by E1B 19K occurred at the level of mitochondria, and delayed release of mitochondrial proteins and prevented caspase-9 and -3 activation. Furthermore, the disruption of p53 apoptotic signaling at mitochondria by E1B 19K caused the eventual unproductive release of cytochrome c and Smac/ DIABLO from mitochondria, which failed to activate downstream caspases-9 and -3 and conferred resistance to apoptosis. Under conditions where E1B 19K inhibited death signaling through mitochondria, E1B 19K was bound to Bak and perturbed the Bax-Bak interaction. Thus, the E1B 19K protein may disrupt p53-mediated death signaling in all or in part by interacting with Bak.
Conformational changes in Bax and Bak mediated by death receptor signaling, require the generation of tBid and the direct interaction of tBid with both Bax and Bak (Desagher et al., 1999; Eskes et al., 2000; Perez and White, 2000; Wei et al., 2000) . The conformational change in Bax induced by wild-type p53 did not involve the generation of tBid, nor are Bid de®cient mice tumor prone (Yin et al., 1999) which would be expected if Bid was in the p53 signaling pathway. Thus another Bidlike protein must be responsible for promoting conformational changes in Bax and Bax translocation to mitochondria. Potential Bid-like proteins found to be transcriptionally activated by p53, such as PUMA, and NOXA are candidates for the function.
We have shown that the conformational change in Bax and localization of Bax to mitochondria were unaected by expression of adenovirus E1B 19K. However, fractionation of Bax with mitochondria is delayed, but does eventually occur in the presence of E1B 19K, suggesting that the insertion of Bax into mitochondria may be delayed by E1B 19K expression. E1B 19K does disrupt Bax and Bak oligomerization, which may inhibit their ability to form pores in the mitochondrial membranes and to release of cytochrome c and Smac/DIABLO during death receptor signaling . We have observed a delay in the p53-induced interaction between Bax and Bak in the presence of E1B 19K, possibly due to an interaction between E1B 19K and Bak. Thus, E1B 19K may inhibit p53-mediated apoptosis by preventing the formation of functional Bax and Bak containing mitochondrial pores, which would disrupt the normal release of cytochrome c and Smac/DIABLO from mitochondria.
Although the E1B 19K expressing cells did eventually release cytochrome c and Smac/DIABLO, they did not die. Given this unproductive release of cytochrome c and Smac/DIABLO in E1B 19K expressing cells was insucient to facilitate caspase-9 activation, it is likely that even a partial block to the mitochondrial checkpoint can inhibit the apoptotic signaling events downstream of mitochondria. Interestingly E1B 19K expressing cells that had been stimulated to release mitochondrial proteins, were resistant to STS-induced cell death. Thus, E1B 19K expression delays cytochrome c and Smac/DIABLO release, and the eventual release is unproductive and can confer resistance to apoptosis.
It is possible that the eventual release of cytochrome c and Smac/DIABLO in E1B 19K expressing cells may be uncoordinated, or the release may simply occur with delayed kinetics, which may not permit the proper conditions for caspase-9 activation. Alternatively, cytochrome c and Smac/DIABLO release from mitochondria may be delayed but normal, and E1B 19K may have the ability to additionally block apoptosis downstream of mitochondria. The requirement for a synchronous and/or ecient release of mitochondrial apoptosis-inducing proteins may be necessary for the propagation of the apoptotic signal, which would prevent apoptosis induction in conditions of limited mitochondrial damage preventing unnecessary cell death. Therefore it is possible that key regulators of this cellular safeguard mechanism may be the anti-apoptotic Bcl-2 family members, and over-expression of these proteins could lead to cellular transformation in situations of gross mitochondrial damage induced by genotoxic stresses.
Cellular proteins such as Bcl-2, may function similarly to E1B 19K in the inhibition of apoptosis. Bcl-2 is over-expressed in many human tumors, which may prevent cell death, but may also disrupt other normal cellular functions requiring mitochondrial cytochrome c, such as respiration. Tumor cells are known to possess defects in mitochondria respiration (Dang et al., 1997, and references within) . This may result from the activation of apoptotic signaling events in conjunction with over-expression of Bcl-2-like antiapoptotic proteins, thereby permitting the unproductive release and degradation of mitochondrial proteins including cytochrome c. Therefore, the unproductive release and degradation of mitochondrial proteins such as cytochrome c may alter cell metabolism and predispose cells to transformation by creating a cellular environment resistant to apoptosis.
Materials and methods
Antibodies
The following antibodies were used: monoclonal antibody to rat Bax (clone 1D1) that recognizes amino acids 3 ± 16 Generation and maintenance of cell lines p53A cells (Debbas and White, 1993) were used to derive all of the BRK cell lines used in this study. Brie¯y, p53A cells were generated by transforming primary BRK cells with adenovirus E1A and the temperature-sensitive p53 mutant p53 val135 . The An1 and 19K1 cell lines were derived from the p53A cells, by transfection with either the vector control plasmid (An1 cells) or the vector control plus the E1B 19K expression vector pCMV19K (19K1 cells), and selected for G418 resistance. Although both cell lines express equal amounts of p53, the 19K1 cells also stably express the E1B 19K protein, thus are resistant to p53-mediated apoptosis at the permissive temperature (Debbas and White, 1993 V5 and EV V5 cell lines (data not shown). All BRK cell lines were maintained in DMEM at 38.58C. Although data for both pairs of cell lines is not shown for each assay described in this manuscript, both sets were tested in all assays and the results obtained were virtually identical. HeLa cells were treated with TNF-a and cyclohexamide (TNF/CHX) (Perez and White, 2000) and were used as a control for caspase activation.
Viability assays
BRK cell lines were grown at the restrictive temperature (38.58C) to a density of 1610 7 cells/10 cm plate and transferred to the permissive temperature (328C) for 0 to 15 days. Cells treated with 0.5 to 15 mM staurosporin (STS) in DMSO or DMSO alone were incubated for 24 h and assayed for viability. Cell viability was determined using either Trypan blue exclusion (White and Cipriani, 1990) or by FACS analysis following staining with propidium iodide (Sabbatini et al., 1995b) .
Indirect immunofluorescence and Western blotting
BRK cell lines were grown on coverslips to a density of 2610 6 cells/6 cm plate at the restrictive temperature of 38.58C, and were transferred to the permissive temperature of 328C for 0 to 10 days. The BRK cells on coverslips were ®xed, and stained for Bax, cytochrome c, or Smac/DIABLO as previously described (Perez and White, 1998; . Indirect immuno¯uorescence using the Smac/DIABLO antibody required epitope retrieval prior to staining . Proteins contained in whole cell extracts were separated by SDS ± PAGE and semidry blotted onto polyvinylidene¯uoride (PVDF) membranes (Schleicher and Schuell, Keene, NH, USA) as previously described (Perez and White, 1998) .
Immunoprecipitation
The EV V5 and 19K V5 cells were grown to a density of 1610 7 cells/10 cm plate at the restrictive temperature (38.58C), and transferred to the permissive temperature (328C) for 0 to 10 days. Cells were harvested and extracts prepared in either CHAPS lysis buer or CHAPS plus Triton X-100 lysis buer, and immunoprecipitations were performed as previously described (Perez and White, 2000; . Whole cell lysates and immunoprecipitations were analysed using SDS ± PAGE and Western blotting as described above.
Cell fractionation
An1 and 19K1 cells were incubated at 38.5 or 328C for 0 to 10 days, harvested, and fractionated as previously described . Brie¯y, cells were lysed by passage through a syringe in 10 mM HEPES pH 7.4, 0.32 M sucrose, 42 mM KCl, 5 mM MgCl 2 , 2 mM EDTA, supplemented with protease inhibitors; to obtain the total cell lysate. Lysates were subjected to low-speed centrifugations to retrieve mitochondria and heavy membranes. The supernatant was then subjected to a high-speed centrifugation step to obtain the soluble S100 fraction, representing the cytosolic proteins. The proteins within the various fractions were analysed via SDS ± PAGE and Western blotting.
